Annexin V was formerly called vascular anticoagulant a (8) , and is known to inhibit the binding of coagulant factors Xa and Va to phosphatidylserine (PS) on the exposed surfaces of activated platelets due to its phos pholipid-binding property. It is also known to inhibit the activation of factor X (9) and the production of thrombin (8) . PS is usually localized on the inner plasma mem brane, but it is exposed on the outer membrane when cells are injured and platelets are activated. When PS is exposed on the surfaces of endothelial cells and platelets, annexin V is thought to prevent concentration of coagu lant factors in PS-rich domains on cell surfaces and amplification of the coagulation response in the blood coagulation cascade (10) .
* To whom correspondence should be addressed. Tel: +81-3-5978 5345, Fax: +81-3-5978-5345, E-mail: kyoko@cc.ocha.ac.jp Sulfatide (galactosylceramide I3-sulfate), a sulfated glycosphingolipid, exists on the surface of oligodendro cytes (11) , erythrocytes (12) , and platelets (13) . Sulfatide is thought to have complicated functions in coagulation systems. Formerly, it was thought that sulfatide activates blood coagulation factor ? in vitro (14) . Recently, it was shown that sulfatide also has strong anticoagulant activ ity that prolongs the anticoagulation time and bleeding time in vivo, and that it interacts with fibrinogen (15) . On the other hand, it has been reported that sulfatide pro motes thrombus formation due to vein ligation in the rat deep vein thrombosis model (16, 17) . Moreover, the inter action between sulfatide and P-selectin, both of which are expressed on platelets, is important in platelet adhesion and aggregation, and causes the formation of fibrin clots (18 
RESULTS

AND DTSCUSSION
Annexin V Bound to Sulfatide-In this study, we examined the interaction between annexin V and sul fatide using several assay systems: glycolipids were adsorbed on a plastic or thin-layer silica plate surface, and then solid-phase binding to annexin V was exam fined. First, annexin V was incubated with sulfatide in the presence of calcium ions on a plastic plate, and then annexin V bound to the sulfatide was detected with anti annexin V antibodies.
On a microtiter plate, annexin V bound only to sulfatide among the glycolipids tested in the presence of calcium ions (Fig. 1) . Annexin V failed to bind to galactosylceramide or ceramide, which are con stituents of sulfatide.
Further, annexin V did not bind to gangliosides GM1 and GM3, even though they have a negatively charged sialic acid. In the absence of calcium ions, annexin V did not bind to sulfatide (data not shown). These results suggested that annexin V does not recognize the sulfate groups of sulfatide through a simple electrostatic interaction. Moreover, to determine the binding specificity to sul fatide, we performed a dose-dependent assay. Sulfatide mixed with PC, to which annexin V does not bind, in var ious ratios was immobilized on a microtiter plate, and then binding of annexin V was assayed in the same way. Annexin V bound to sulfatide in a dose-dependent man jig aliquots of lipids were chromatographed on TLC plates. Glycolip ids were visualized with orcinol-sulfuric acid (A). The binding of annexin V to various lipids was examined on TLC plates (B). TLC plates were incubated with biotinylated-GST-annexin V in the pres ence of 5 mM CaCl2, followed by detection with streptavidin-peroxi dase.
ner in the presence of calcium ions (Fig. 2) . Next, we examined the binding of annexin V to sulfatide directly on the TLC silica plate surface. Annexin V was labeled with biotin in order to increase the level of detection and to reduce the number of steps in the experiment.
We used GST-annexin V for biotinylation to prevent artificial inac tivation of annexin V through modification of the amino groups important for the interaction with sulfatide. On the TLC plate, annexin V also bound only to sulfatide, i.e. not to gangliosides or galactosylceramide (Fig. 3 ), in agreement with the results of the microtiter plate assay (Fig. 1) Fig. 4 , annexin V exhibited binding activity toward sulfatide in the presence of mM levels of calcium ions. Since the concentrations of calcium ions in the extracellular spaces and blood are of mM order, the interaction of annexin V with sulfatide in the blood circu lation is feasible as a physiological phenomenon.
Kinetics of Interaction between Annexin V and Sul fatide-To determine the binding parameters of the interaction between annexin V and sulfatide, we per formed surface plasmon resonance assays using the BIAcore system. Liposomes were prepared with sulfatide and PC, which was used as a control, in a ratio of 1:9 and then immobilized on a HPA chip. Various concentrations of annexin V were allowed to flow over the chip in the presence of 1 mM calcium ions. The amount of lipid immobilized at 10% sulfatide-90% PC was 1,700 response units (RU); for PC alone, it was 2,000 RU. The sensorgram of sulfatide was subtracted from that of PC alone as a control, as shown in Fig. 5A . Under the same conditions, BSA did not bind to sulfatide or PC (data not Effect of Annexin V on Plasma Coagulation Activity of Sulfatide-It has been reported that sulfatide exhibits coagulation activity that accelerates the coagulation of plasma, and that the activity is factor ?-dependent (17) . Annexin V is known as an anticoagulant factor because it prevents the concentration of coagulant factors in PS-rich domains and amplification of the coagulation response in the blood coagulation cascade (10); however, the effect of annexin V on the activity of sulfatide in blood coagulation has not been studied. To determine whether or not annexin V affects the coagulant activity of sul fatide, we next performed kinetic turbidometric assaying of plasma coagulation initiated by CaC12. In this experi ment, we used GST-annexin V because GST-free annexin V is contaminated by factor Xa, which is used as a pro tease for cleavage of the linker region between GST and annexin V. Factor Xa is a blood coagulation factor and contamination by it in the assay is inconvenient. As shown in Fig. 6A , sulfatide started to coagulate plasma at 4.3 min and remarkably increased the coagulation rate in comparison to in a non-lipid control well, where coagula tion started at 20 min. These results agree with previous reports (16, 17) . Sulfatide is thought to activate factor ?
, the factor that starts the coagulation cascade, sug Mechanism Underlying Anticoagulant Activity of Annexin V-Coagulability, the balance between blood coagulation and fibrinolysis in the blood circulation, is regulated through complex mechanisms in which many steps and a variety of molecules are involved. Annexin V has been considered one of the modulatory molecules for coagulation in the blood circulation. The amount of annexin V in the blood is 1.7 ng/ml (23), and there have been several reports of anticoagulant activity of annexin V in vivo. Fibrin accretion on injured vessel walls decreased when annexin V was administered to rabbit jugular veins injured by air perfusion (24), and annexin V exhibited significant antithrombotic activity when it was administered to veins in a laser-induced thrombosis for mation model rat (25). Recently, the hypothesis that annexin V has a thrombomodulatory function on the sur faces that line the placental and systemic vasculature has been supported by epidemiological studies. It has been reported that annexin V plays roles in the physio logical control of blood coagulation reactions and also that abnormalities of annexin V expression are associ ated with clinical diseases: annexin V is decreased on placental trophoblasts and on endothelial cells in the Sulfatide exists in the blood circulation as a cell sur face molecule on erythrocytes (12) and platelets (13) . Fac tor ?
is activated in the presence of prekallikrein and high molecular weight kininogen with negatively charged inorganic surfaces (glass and kaolin), and macro molecules with biological properties (collagen, GAG, lipopolysaccharide, and amyloid (3). Sulfatide is thought to exhibit the same activity toward negatively charged surfaces and to initiate the blood coagulation cascade; however, it is not clear how much sulfatide contributes to the regulation of blood coagulability in vivo. Cerebroside sulfotransferase-null mice, which do not express sulfated glycolipids such as sulfatide and seminolipid, have already been produced. These mice exhibit abnormalities in myelin function and spermatogenesis (27), but no abnormality in blood coagulation systems was found under the optimized conditions. 
